Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full News1.
Biocomputer From Human Neurons Plays Doom, Raises Ethics
2.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
3.
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
4.
Nuclear missile workers are contracting cancer: They blame the bases
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps
2.
Myeloid-Derived Suppressor Cells Beyond Cancer: Expanding Roles in Health and Disease
3.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
4.
Emerging Therapies Using Targeted Antibody–Drug Conjugates Against Previously Difficult Tumor Targets
5.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
How Hematologists Evaluate Persistent Blood Abnormalities
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Managing Common Side Effects During Cancer Treatment
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation